Batiraxcept
- Generic Name
- Batiraxcept
- Drug Type
- Biotech
- CAS Number
- 2268717-61-7
- Unique Ingredient Identifier
- B6840JH4EB
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- Conditions
- Recurrent High Grade Uterine Cancer
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT05826015
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04983407
- Locations
- 🇺🇸
UCLA Health, Santa Monica, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Boca Raton Regional Hospital / Lynn Cancer Institute, Boca Raton, Florida, United States
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04729608
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Columbus NCORP, Columbus, Ohio, United States
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04300140
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04042623
- Locations
- 🇺🇸
Moonshine Clinical Research, Doral, Florida, United States
🇺🇦Institute of Nephrology National Academy of Medical Science Ukraine, Kyiv, Ukraine
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Refractory Ovarian CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRefractory Fallopian Tube CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRefractory Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT04019288
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 19
- Registration Number
- NCT04004442
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03639246
- Locations
- 🇺🇸
OUHSC-Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Kaiser Permanente Vallejo, Vallejo, California, United States
🇺🇸Kaiser Permanente San Francisco, San Francisco, California, United States
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
- Interventions
- Procedure: Tissue from Diagnostic LaparoscopyProcedure: Tissue from Core biopsyProcedure: Interval DebulkingProcedure: Peripheral bloodProcedure: Ascites collection
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT03607955
A Phase 1 AVB-S6-500 Safety and Tolerability Study
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03401528
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.